keyword
MENU ▼
Read by QxMD icon Read
search

Adalimumab

keyword
https://www.readbyqxmd.com/read/28211631/editorial-relative-efficacy-of-infliximab-and-adalimumab-in-crohn-s-disease-in-an-australian-and-new-zealand-cohort-authors-reply
#1
EDITORIAL
G L Radford-Smith, F Hartnell, J D Doecke
No abstract text is available yet for this article.
March 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28211628/editorial-relative-efficacy-of-infliximab-and-adalimumab-in-crohn-s-disease-in-an-australian-and-new-zealand-cohort
#2
EDITORIAL
M Barreiro-de Acosta, J P Gisbert
No abstract text is available yet for this article.
March 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28211161/psoriasis-and-psoriasiform-eruptions-in-pediatric-patients-with-inflammatory-bowel-disease-treated-with-anti-tumor-necrosis-factor-alpha-agents
#3
Joshua B Eickstaedt, Luke Killpack, Jeanne Tung, Dawn Davis, Jennifer L Hand, Megha M Tollefson
BACKGROUND: Anti-tumor necrosis factor alpha (TNF-α) agents are used to treat a variety of autoimmune and inflammatory conditions, including psoriasis. Paradoxically, numerous reports have documented new-onset or exacerbation of psoriasis or psoriasiform skin lesions (PSO) in patients treated with these agents for conditions other than PSO-particularly in adults with inflammatory bowel disease (IBD). Not much is known regarding similar cases in children. METHODS: A retrospective chart review was performed on children younger than 19 years of age with IBD seen at the Mayo Clinic between 2003 and 2015 who developed new-onset or recurrent PSO while undergoing anti-TNF-α therapy...
February 17, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28209290/efficacy-safety-and-pharmacokinetics-of-biosimilars-of-anti-tumor-necrosis-factor-%C3%AE-agents-in-rheumatic-diseases-a-systematic-review-and-meta-analysis
#4
REVIEW
Yuga Komaki, Akihiro Yamada, Fukiko Komaki, Praneeth Kudaravalli, Dejan Micic, Akio Ido, Atsushi Sakuraba
OBJECTIVE: To evaluate the efficacy and safety of biosimilars of anti-tumor necrosis factor (TNF)-α agents compared to their reference agents in immune mediated diseases. METHODS: Electronic databases were searched for randomized controlled trials (RCTs) assessing the efficacy and safety of biosimilars of anti-TNF-α agents compared to their reference agents in patients with various immune mediated diseases. The outcomes were the rates of clinical response and adverse events among patients treated with biosimilars compared to their reference agents...
February 13, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/28201720/rapid-healing-of-peripheral-ulcerative-keratitis-in-rheumatoid-arthritis-with-prednisone-methotrexate-and-adalimumab-combination-therapy
#5
Peter Korsten, Dirk Bahlmann, Susann A Patschan
No abstract text is available yet for this article.
February 14, 2017: Rheumatology
https://www.readbyqxmd.com/read/28199814/baricitinib-versus-placebo-or-adalimumab-in-rheumatoid-arthritis
#6
Peter C Taylor, Edward C Keystone, Désirée van der Heijde, Michael E Weinblatt, Liliana Del Carmen Morales, Jaime Reyes Gonzaga, Sergey Yakushin, Taeko Ishii, Kahaku Emoto, Scott Beattie, Vipin Arora, Carol Gaich, Terence Rooney, Douglas Schlichting, William L Macias, Stephanie de Bono, Yoshiya Tanaka
Background Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that may have therapeutic value in patients with rheumatoid arthritis. Methods We conducted a 52-week, phase 3, double-blind, placebo- and active-controlled trial in which 1307 patients with active rheumatoid arthritis who were receiving background therapy with methotrexate were randomly assigned to one of three regimens in a 3:3:2 ratio: placebo (switched to baricitinib after 24 weeks), 4 mg of baricitinib once daily, or 40 mg of adalimumab (an anti-tumor necrosis factor α monoclonal antibody) every other week...
16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28196270/open-label-study-of-etanercept-treatment-in-patients-with-moderate-to-severe-plaque-psoriasis-who-lost-a-satisfactory-response-to-adalimumab
#7
J Bagel, S Tyring, K C Rice, D H Collier, G Kricorian, J Chung, J Iles, B S Stolshek, A Kaliyaperumal, K A Papp
BACKGROUND: Some plaque psoriasis patients experience secondary failure of tumour necrosis factor inhibitor therapy. OBJECTIVES: To evaluate efficacy, safety, and patient-reported outcomes (PROs) with etanercept in patients with secondary adalimumab failure. METHODS: This phase 4, open-label, single-arm, estimation study (NCT01543204) enrolled patients on adalimumab who had achieved static physician global assessment (sPGA) score 0/1 (clear/almost clear)...
February 14, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28194815/peristomal-psoriasis
#8
C Marshall, S Woodmansey, C C Lyon
BACKGROUND: Psoriasis is a common skin condition, affecting 1.3-2.2% of the population. The prevalence of psoriasis has previously been reported as 11.2% in patients with Crohn disease (CD) and 5.7% in patients with ulcerative colitis. AIM: To assess the prevalence of psoriasis around stoma sites and identify the most effective treatment. METHODS: A departmental database of all patients attendings stoma clinic was accessed between 1 May 2003 and 15 October 2015...
February 13, 2017: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/28191663/a-case-of-lupus-like-syndrome-in-a-patient-receiving-adalimumab-and-a-brief-review-of-the-literature-on-drug-induced-lupus-erythematosus
#9
I Lomicová, D Suchý, K Pizinger, P Cetkovská
WHAT IS KNOWN AND OBJECTIVE: Drug-induced lupus erythematosus occurs with some drugs and resolves with their withdrawal. Anti-TNF therapies have been found to be associated with a lupus-like syndrome, which is clinically distinct from classical drug-induced as well as idiopathic lupus erythematosus. CASE DESCRIPTION: We describe a case of a patient with severe psoriasis, who developed muscle pain with paraesthesia accompanied by ANA titres elevation with adalimumab treatment...
February 12, 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/28179246/legionella-pneumophila-pneumonia-possibly-due-to-ustekinumab-therapy-in-a-patient-with-crohn-s-disease
#10
Joaquín Borrás-Blasco, Xavier Cortes, Sergio Fernandez-Martinez, Elvira Casterá, Beatriz Antequera
PURPOSE: A case report of Legionella pneumophila pneumonia associated with off-label use of ustekinumab in a patient with Crohn's disease (CD) is presented. SUMMARY: A 57-year-old man with longstanding CD was hospitalized with a four-day history of fever (38.5 °C), dyspnea, left pleuritic pain, and weight loss (more than 6 kg) about six weeks after beginning treatment with ustekinumab, a human monoclonal antibody approved in the United States for two indications (plaque psoriasis and psoriatic arthritis) and currently under investigation as a potential treatment for CD and other inflammatory disorders...
February 15, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28176188/adalimumab-for-treating-moderate-to-severe-hidradenitis-suppurativa-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#11
REVIEW
Paul Tappenden, Christopher Carroll, John W Stevens, Andrew Rawdin, Sabine Grimm, Mark Clowes, Eva Kaltenthaler, John R Ingram, Fiona Collier, Mohammad Ghazavi
As part of its single technology appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of adalimumab (AbbVie) to submit evidence on the clinical effectiveness and cost effectiveness of adalimumab for the treatment of moderate-to-severe hidradenitis suppurativa (HS). The appraisal assessed adalimumab as monotherapy in adult patients with an inadequate response to conventional systemic HS therapy. The School of Health and Related Research Technology Appraisal Group was commissioned to act as the independent Evidence Review Group (ERG)...
February 7, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28175273/n811-infliximab-versus-adalimumab-clinical-and-endoscopy-response-in-ulcerative-colitis-patients-a%C3%A2-prospective-study
#12
R P L Silva, G C Bissoli, E Farinelli, C F Sibia, J R Barros, F L Renosto, R S Hossne, J P Baima, L Y Sassaki
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175238/p666-short-term-outcomes-of-adalimumab-for-patients-with-crohn-s-disease-and-associated-prognostic-factors-a-multicentre-retrospective-cohort-study
#13
M Nasuno, H Tanaka, M Miyakawa, S Motoya, M Ishii, A Shiotani, M Yamashita, F Itoh, T Tanuma, R Sakemi, S So, R Suzuki, H Yanagisawa, K Onodera, H Kaneto, M Nojima, H Nakase
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175235/p699-impact-of-adalimumab-s-patient-support-program-on-clinical-outcomes-in-inflammatory-bowel-diseases-results-from-the-companion-study
#14
J K Marshall, N Narula, G Lebovic, B Millson, K Charland, M Sung, T Gaetano, K McHugh, M Latour, M-C Laliberte
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175203/p593-hospital-resource-use-and-cost-associated-with-first-line-anti-tnf-therapy-in-patients-with-ibd-in-the-uk-comparison-of-subcutaneous-adalimumab-and-intravenous-infliximab-therapies
#15
J Hickey, S Keshav, S Gaugris, R Arasaradnam
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175202/p674-potential-utility-of-therapeutic-drug-monitoring-of-adalimumab-in-predicting-short-term-mucosal-healing-and-histologic-remission-in-paediatric-crohn-s-disease-patients
#16
B Kang, K Lee, B-H Choe, Y H Choe
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175201/p676-comparison-of-real-world-outcomes-of-adalimumab-and-infliximab-for-patients-with-ulcerative-colitis-in-the-united-states
#17
W Sandborn, A Sakuraba, A Wang, D Macaulay, L Schemerold, M Yang, M Skup
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175194/p669-adalimumab-long-term-effectiveness-in-adalimumab-na%C3%A3-ve-patients-with-crohn-s-disease-final-data-from-pyramid-registry
#18
E Loftus, G D'Haens, W Reinisch, J Satsangi, R Panaccione, S Berg, G Alperovich, M Bereswill, J Kalabic, M Skup, J Petersson, A M Robinson
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175165/p641-long-term-outcome-of-adalimumab-therapy-and-predictors-of-response-in-254-patients-with-crohn-s-disease-a-hospital-based-cohort-study-from-korea
#19
H Seo, B D Ye, S-H Lee, K Chang, E M Song, G-U Kim, M Seo, H-S Lee, S W Hwang, S H Park, D-H Yang, K-J Kim, J-S Byeon, S-J Myung, S-K Yang
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175152/p449-patient-support-program-for-adalimumab-treated-patients-with-crohn-s-disease-in-brazil-impact-on-patients-adherence-and-persistence
#20
V Teich, R Arinelli, A Gulart, L Chaves, V Garg, M Skup
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
keyword
keyword
1884
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"